Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
Rakuten Medical’s ASP-1929, an antibody drug conjugate (ADC) that works on its unique “photoimmunotherapy” platform, is now under Japanese regulatory review for the treatment of recurrent head and neck cancer under the conditional, early approval pathway. The San Mateo, California-based…
To read the full story
Related Article
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
- Rakuten Medical Gears Up for Global Pitch on Photoimmunotherapy: Chairman
August 4, 2023
- Rakuten Medical Eyes Label Expansion for Photoimmunotherapy, Asia as Key Market
August 26, 2021
- Rakuten Medical’s Photoimmunotherapy Now Available in Japan
February 9, 2021
- After Photoimmunotherapy Nod, Rakuten’s Mikitani Says Company Is Finally at Start Line
September 30, 2020
- Mikitani Resolved to Grow Rakuten Medical into Global Biotech
July 2, 2019
- Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
- Rakuten Medical’s Photoimmunotherapy Demonstrates Favorable Tolerability in PIIa
June 4, 2019
- Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More
April 9, 2019
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…